

I. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

Claim 1-11. (Cancelled)

Claim 12. (previously presented) An oral dosage form comprising:

- (i) an analgesically effective amount of an orally active opioid agonist; and
- (ii) naltrexone or a pharmaceutically acceptable salt thereof;

said opioid agonist and naltrexone or pharmaceutically acceptable salt thereof being chosen such that the opioid agonist and the naltrexone or pharmaceutically acceptable salt thereof are only extractable from the dosage form together, and at least a two-step extraction process is required to separate the opioid antagonist from the naltrexone or pharmaceutically acceptable salt thereof, the amount of naltrexone or pharmaceutically acceptable salt thereof included being sufficient to counteract opioid effects if extracted from the oral dosage form together with the opioid agonist and administered parenterally.

Claim 13. (previously presented) The oral dosage form of claim 12, wherein the opioid agonist is hydromorphone hydrochloride and the naltrexone or pharmaceutically acceptable salt thereof is naltrexone hydrochloride.

Claim 14. (previously presented) The oral dosage form of claim 12, wherein the opioid agonist is oxycodone hydrochloride and the naltrexone or pharmaceutically acceptable salt thereof is naltrexone hydrochloride.

Claim 15. (previously presented) The oral dosage form of claim 12, wherein the opioid agonist is morphine sulfate and the naltrexone or pharmaceutically acceptable salt thereof is naltrexone hydrochloride.

Claim 16. (previously presented) The oral dosage form of claim 12, wherein the opioid agonist is hydrocodone bitartrate and the naltrexone or pharmaceutically acceptable salt thereof is naltrexone hydrochloride.

Claim 17. (previously presented) The oral dosage form of claim 12, wherein the opioid agonist is hydromorphone hydrochloride and the ratio of said naltrexone to said hydromorphone is from about 0.148:1 to about 1.185:1 by weight.

Claim 18. (previously presented) The oral dosage form of claim 12, wherein the opioid agonist is hydromorphone hydrochloride and the ratio of said naltrexone to said hydromorphone is from about 0.222:1 to about 0.111:1 by weight.

Claim 19. (previously presented) The oral dosage form of claim 12, wherein the opioid agonist is morphine sulfate and the ratio of said naltrexone to said morphine is from about 0.018:1 to about 1.148:1 by weight.

Claim 20. (previously presented) The oral dosage form of claim 12, wherein the opioid agonist is oxycodone hydrochloride and the ratio of said naltrexone to said oxycodone is from about 0.037:1 to about 0.296:1 by weight.

Claim 21. (previously presented) The oral dosage form of claim 12, wherein the opioid agonist is oxycodone hydrochloride and the ratio of said naltrexone to said oxycodone is from about 0.056:1 to about 0.222:1 by weight.

Claim 22. (previously presented) The oral dosage form of claim 12, wherein the opioid agonist is hydrocodone bitartrate and the ratio of said naltrexone to said hydrocodone is from about 0.03:1 to about 0.27:1 by weight.

Claim 23. (previously presented) The oral dosage form of claim 12, further comprising a sustained release carrier, wherein the sustained release carrier provides for a release of said opioid agonist such that the dosage form is suitable for administration on a twice-a-day or a once-a-day basis.